Tacrolimus extended-release - Veloxis Pharmaceuticals

Drug Profile

Tacrolimus extended-release - Veloxis Pharmaceuticals

Alternative Names: Envarsus; EnvarsusXR; LCP-Tacro™; MeltDose® tacrolimus tablets; Tacrolimus extended release; Tacrolimus-ER

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator LifeCycle Pharma
  • Developer LifeCycle Pharma; Veloxis Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Liver transplant rejection; Renal transplant rejection
  • Discontinued Autoimmune disorders

Most Recent Events

  • 28 Nov 2016 Chiesi Farmaceutici plans a phase II trial for Renal transplant rejection in Italy (NCT02970630)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Dec 2015 Launched for Renal transplant rejection (Combination therapy, Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top